SCHEMBL5464385

SCHEMBL5464385

CC1(C)CC=C(c2cc(C3(O)CCN(CC(F)(F)F)CC3)ccc2N)CC1

nearest known ligand 0.57

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 4/20 0.35
▸ OPRK1 P41145 3/20 0.35
▸ OPRD1 P41143 2/20 0.35
▸ OPRL1 P41146 5/20 0.34
▸ CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464380 0.87 OPRM1 (0.36) OPRM1OPRK1OPRD1CSF1R
SCHEMBL3971778 0.84 — —
SCHEMBL5645101 0.81 — —
SCHEMBL5481061 0.80 CSF1R (0.38) CSF1R
SCHEMBL5648537 0.80 — —
SCHEMBL5651404 0.79 — —
SCHEMBL5476666 0.78 — —
SCHEMBL3164439 0.78 — —
SCHEMBL16320638 0.77 — —
SCHEMBL14374723 0.76 CSF1R (0.46) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 — — US disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 — — EP disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 — — US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 — — US disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES OPRM1 890/4885OPRK1 307/4885OPRD1 1774/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES OPRM1 890/4885OPRK1 307/4885OPRD1 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback